Education
About Us
Working with TipRanks
Follow Us
Ventyx Biosciences (VTYX)
NASDAQ:VTYX
VTYX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.78 - $3.39
Previous CloseN/A
Volume4.54M
Average Volume (3M)1.12M
Market Cap
$188.25M
Enterprise Value-$46.30M
Total Cash (Recent Filing)$228.81M
Total Debt (Recent Filing)$10.55M
Price to Earnings (P/E)―
Beta2.12
Next Earnings
Nov 12, 2025EPS Estimate
-0.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding71,308,520
10 Day Avg. Volume923,276
30 Day Avg. Volume1,120,698
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.25
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit146.52
Enterprise Value/Ebitda0.34
Forecast
1Y Price Target
$11.40Price Target Upside333.46% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessVentyx reported positive results from the Phase IIa open-label study for VTX3232 in early Parkinson's disease.
Safety ProfileVTX3232 demonstrated a well tolerated profile with no drug-related TEAEs or SAEs over the 28d dosing-period.
Treatment InnovationThe VTX2735 trial for recurrent pericarditis is on track, with the potential to offer a more convenient oral treatment option compared to current injectable therapies.
Bears Say
Competitive MarketA significant increase over semaglutide alone is needed to justify the combination approach, presenting a challenge for the company's strategy.
Strategic AlliancesThe pressure on VTYX relates to a lack of concurrent update on interactions with Sanofi, which maintains right of 1st negotiation for VTX3232.
Strategic ChallengesThe company is not focusing on monotherapy for obesity as the market is highly competitive, indicating challenges in this strategy.
Ventyx Biosciences News
VTYX FAQ
What was Ventyx Biosciences’s price range in the past 12 months?
Ventyx Biosciences lowest stock price was $0.78 and its highest was $3.39 in the past 12 months.
What is Ventyx Biosciences’s market cap?
Ventyx Biosciences’s market cap is $188.25M.
When is Ventyx Biosciences’s upcoming earnings report date?
Ventyx Biosciences’s upcoming earnings report date is Nov 12, 2025 which is in 91 days.
How were Ventyx Biosciences’s earnings last quarter?
Ventyx Biosciences released its earnings results on Aug 07, 2025. The company reported -$0.38 earnings per share for the quarter, beating the consensus estimate of -$0.47 by $0.09.
Is Ventyx Biosciences overvalued?
According to Wall Street analysts Ventyx Biosciences’s price is currently Undervalued.
Does Ventyx Biosciences pay dividends?
Ventyx Biosciences does not currently pay dividends.
What is Ventyx Biosciences’s EPS estimate?
Ventyx Biosciences’s EPS estimate is -0.46.
How many shares outstanding does Ventyx Biosciences have?
Ventyx Biosciences has 71,308,520 shares outstanding.
What happened to Ventyx Biosciences’s price movement after its last earnings report?
Ventyx Biosciences reported an EPS of -$0.38 in its last earnings report, beating expectations of -$0.47. Following the earnings report the stock price went up 19.068%.
Which hedge fund is a major shareholder of Ventyx Biosciences?
Currently, no hedge funds are holding shares in VTYX
Ventyx Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.40 (333.46% Upside)
$11.40 (333.46% Upside)
Blogger Sentiment
Bearish
VTYX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 440.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 2.4%
Last 30 Days ▼ 2.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
27.53%
12-Months-Change
Fundamentals
Return on Equity
-48.56%
Trailing 12-Months
Asset Growth
-25.61%
Trailing 12-Months
Company Description
Ventyx Biosciences
Ventyx Biosciences (VTYX) is a clinical-stage biopharmaceutical company focused on discovering and developing novel, small molecule drugs for the treatment of inflammatory and autoimmune diseases. The company is engaged in the research and development of therapies targeting clinically validated mechanisms, with an emphasis on addressing significant unmet medical needs. Ventyx's core product candidates are designed to modulate key pathways involved in immune system regulation, providing potential new treatments for conditions such as psoriasis, Crohn's disease, and ulcerative colitis.
VTYX Stock 12 Month Forecast
Average Price Target
$11.40
▲(333.46% Upside)
Technical Analysis
Assembly Biosciences
―
Acumen Pharmaceuticals
―
TScan Therapeutics
―
Context Therapeutics
―
Rani Therapeutics Holdings
―
Ownership Overview
9.75% Insiders
9.42% Mutual Funds
0.06% Other Institutional Investors
75.52% Public Companies and
Individual Investors